[{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Hematology","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Translational Sciences, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Hematology","graph2":"Phase I","graph3":"Translational Sciences, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Sciences, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Translational Sciences, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"CSL","sponsor":"Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Hematology","graph2":"Phase I","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL \/ Translational Sciences","highestDevelopmentStatusID":"6","companyTruncated":"CSL \/ Translational Sciences"},{"orgOrder":0,"company":"AegisCN","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CN-105","moa":"Apolipoprotein E (APOE)","graph1":"Hematology","graph2":"Phase I","graph3":"AegisCN","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AegisCN \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AegisCN \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AZD0466","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Hematology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"iCell Gene Therapeutics","sponsor":"iCell ImmunityX","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCMA-CD19 cCAR-T Cell","moa":"B-cell maturation antigen\/CD19","graph1":"Hematology","graph2":"Phase I","graph3":"iCell Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"iCell Gene Therapeutics \/ iCell ImmunityX","highestDevelopmentStatusID":"6","companyTruncated":"iCell Gene Therapeutics \/ iCell ImmunityX"},{"orgOrder":0,"company":"Hrain Biotechnology","sponsor":"Shanghai Changzheng Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Hematology","graph2":"Phase I","graph3":"Hrain Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hrain Biotechnology \/ Shanghai Changzheng Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Hrain Biotechnology \/ Shanghai Changzheng Hospital"},{"orgOrder":0,"company":"Ouro Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"OM336","moa":"BCMA | CD3","graph1":"Hematology","graph2":"Phase I","graph3":"Ouro Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ouro Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ouro Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Pluri","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Hematology","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BIVV020","moa":"C1S","graph1":"Hematology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"aptamers||CCL2","graph1":"Hematology","graph2":"Phase I","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Suzhou Fundamenta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CAR-T-19A","moa":"CD19","graph1":"Hematology","graph2":"Phase I","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Suzhou Fundamenta Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Suzhou Fundamenta Therapeutics"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Hematology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Juventas Cell Therapy","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CNCT19","moa":"CD19","graph1":"Hematology","graph2":"Phase I","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Juventas Cell Therapy","highestDevelopmentStatusID":"6","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Juventas Cell Therapy"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Inserm","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CTL19","moa":"CD19","graph1":"Hematology","graph2":"Phase I","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nantes University Hospital \/ INSERM","highestDevelopmentStatusID":"6","companyTruncated":"Nantes University Hospital \/ INSERM"},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Inaticabtagene Autoleucel","moa":"CD19","graph1":"Hematology","graph2":"Phase I","graph3":"Juventas Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juventas Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Juventas Cell Therapy \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD7 CAR-T Cell","moa":"CD7","graph1":"Hematology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD7 CAR-T Cell","moa":"CD7","graph1":"Hematology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"Bristol Myers Squibb | CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Prothrombin Complex Concentrate","moa":"Coagulation factor","graph1":"Hematology","graph2":"Phase I","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Thomas Jefferson University \/ Bristol Myers Squibb | CSL Behring","highestDevelopmentStatusID":"6","companyTruncated":"Thomas Jefferson University \/ Bristol Myers Squibb | CSL Behring"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"N9-GP","moa":"Coagulation factor IX (F9)","graph1":"Hematology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Bleeding and Clotting Disorders Institute Peoria, Illinois","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Hematology","graph2":"Phase I","graph3":"Bleeding and Clotting Disorders Institute Peoria, Illinois","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bleeding and Clotting Disorders Institute Peoria, Illinois \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Bleeding and Clotting Disorders Institute Peoria, Illinois \/ Genentech"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Eptacog Alfa","moa":"Coagulation factor VII","graph1":"Hematology","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"HPAPI","year":"2012","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Pfizer Inc"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase I","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bayer AG \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Milvexian","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Milvexian","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Milvexian","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Milvexian","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Milvexian","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Milvexian","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Milvexian","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Milvexian","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Milvexian","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"EP-7041","moa":"Coagulation factor XI (F11)","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MK-2060","moa":"Coagulation factor XI (F11)","graph1":"Hematology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Aronora","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Xisomab 3G3","moa":"Coagulation factor XI reciprocal","graph1":"Hematology","graph2":"Phase I","graph3":"Aronora","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aronora \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aronora \/ Undisclosed"},{"orgOrder":0,"company":"Aronora","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Thrombin","moa":"Coagulation factor XI; Coagulation factor XIII A chain; Coagulation factor XIII B chain; Fibrinogen alpha chain; Fibrinogen beta chain; Fibrinogen gamma chain; Coagulation factor V; Coagulation factor VIII; Proteinase-activated receptor 1; Proteinase-activated receptor 4","graph1":"Hematology","graph2":"Phase I","graph3":"Aronora","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aronora \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aronora \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SAR445088","moa":"Complement C1s component (C1S)","graph1":"Hematology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Step Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"STP938","moa":"CTPS1","graph1":"Hematology","graph2":"Phase I","graph3":"Step Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Step Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Step Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Hematology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Hematology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Posaconazole","moa":"Cytochrome P450 51","graph1":"Hematology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"BI655075","moa":"Dabigatran","graph1":"Hematology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GSK4172239D","moa":"DNMT1","graph1":"Hematology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"APG-5918","moa":"EED","graph1":"Hematology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"4SC AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"4SC-202","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Hematology","graph2":"Phase I","graph3":"4SC AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4SC AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"4SC AG \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DA3880","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Darbepoetin alfa","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Seoul National University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Darbepoetin alfa","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Seoul National University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Bio Sidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ARGENTINA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Bio Sidus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Sidus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio Sidus \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Asundexian","moa":"F11a||FXIa","graph1":"Hematology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Asundexian","moa":"F11a","graph1":"Hematology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"VarmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase I","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VarmX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VarmX \/ Undisclosed"},{"orgOrder":0,"company":"VarmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase I","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VarmX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VarmX \/ Undisclosed"},{"orgOrder":0,"company":"VarmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase I","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VarmX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VarmX \/ Undisclosed"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"STP122G","moa":"Factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Phase I","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Phase I","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Ferritin light chain; Hemoglobin subunit alpha; Hemoglobin subunit beta","graph1":"Hematology","graph2":"Phase I","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rockwell Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rockwell Medical \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQB2101","moa":"FGFR","graph1":"Hematology","graph2":"Phase I","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Biomedica Management","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Clotfoam","moa":"Fibrin","graph1":"Hematology","graph2":"Phase I","graph3":"Biomedica Management","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Biomedica Management \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Biomedica Management \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-962212","moa":"FXIa","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BRAZIL","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Megalabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BRAZIL","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Megalabs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Megalabs \/ Undisclosed"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fezagepras","moa":"G-protein coupled receptor 84 | Free fatty acid receptor 1","graph1":"Hematology","graph2":"Phase I","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liminal BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Liminal BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fezagepras","moa":"G-protein coupled receptor 84 | Free fatty acid receptor 1","graph1":"Hematology","graph2":"Phase I","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liminal BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Liminal BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"RUSSIA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Filgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Filgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Filgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"HSP-130","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"TPI-120","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Undisclosed"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Undisclosed"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Disc medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"LY2787106","moa":"Hepcidin","graph1":"Hematology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"GSK1278863A","moa":"HIF prolyl hydroxylase","graph1":"Hematology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"14-C GSK1278863","moa":"HIF-PH","graph1":"Hematology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DS-1093","moa":"HIF-prolyl hydroxylase (HPH)","graph1":"Hematology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Prolong Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Pegylated Carboxyhemoglobin Bovine","moa":"Homeostasis","graph1":"Hematology","graph2":"Phase I","graph3":"Prolong Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prolong Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prolong Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"NNC 0128-0000-2011","moa":"Insulin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"NNC 0128-0000-2011","moa":"Insulin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Hematology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"National Cancer Institute | NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"NT-I7","moa":"interleukins: interleukin-7 analogues and derivatives; Fc fusion protein","graph1":"Hematology","graph2":"Phase I","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ National Cancer Institute | NeoImmuneTech","highestDevelopmentStatusID":"6","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ National Cancer Institute | NeoImmuneTech"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Hematology","graph2":"Phase I","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Hematology","graph2":"Phase I","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Sideris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"SP-420","moa":"Iron","graph1":"Hematology","graph2":"Phase I","graph3":"Sideris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sideris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sideris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"AbFero Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SP-420","moa":"Iron","graph1":"Hematology","graph2":"Phase I","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at San Antonio \/ AbFero Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"University of Texas Health Science Center at San Antonio \/ AbFero Pharmaceuticals"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Tardyferon","moa":"Iron","graph1":"Hematology","graph2":"Phase I","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bond Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bond Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bond Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bond Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BLU-263","moa":"KIT","graph1":"Hematology","graph2":"Phase I","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Blueprint Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zaltenibart","moa":"MASP1","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"YL-Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Linperlisib","moa":"PI3K delta","graph1":"Hematology","graph2":"Phase I","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ YL-Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ YL-Pharma"},{"orgOrder":0,"company":"advanceCOR","sponsor":"Procorde GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Revacept","moa":"Platelet glycoprotein VI (GP6)","graph1":"Hematology","graph2":"Phase I","graph3":"advanceCOR","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"advanceCOR \/ Procorde GmbH","highestDevelopmentStatusID":"6","companyTruncated":"advanceCOR \/ Procorde GmbH"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Hematopoietic Stem Cell Transplant","moa":"Progenitor cell","graph1":"Hematology","graph2":"Phase I","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"MD Anderson Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BMS-986120","moa":"Prostate apoptosis response-4 (PAWR)","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Tarix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Angiotensin (1-7)","moa":"Proto-oncogene Mas","graph1":"Hematology","graph2":"Phase I","graph3":"Tarix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tarix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tarix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"POZEN","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Hematology","graph2":"Phase I","graph3":"POZEN","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"POZEN \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"POZEN \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Hematology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"ScinnoHub Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SNH-119014","moa":"Pyruvate kinases","graph1":"Hematology","graph2":"Phase I","graph3":"ScinnoHub Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ScinnoHub Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ScinnoHub Pharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AS703569","moa":"Serine\/threonine-protein kinase Aurora","graph1":"Hematology","graph2":"Phase I","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EMD Serono \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"AK002","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Hematology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Shanghai Xiniao Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Ucar T-Cell","moa":"T-cell","graph1":"Hematology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Shanghai Xiniao Biotech Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Shanghai Xiniao Biotech Co., Ltd."},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Alefacept","moa":"T-cell surface antigen CD2","graph1":"Hematology","graph2":"Phase I","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Astellas Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Cleveland Clinic \/ Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Hematology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Capital Health, Canada | Dalhousie University | Universit\u00e9 de Montr\u00e9al","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Hematology","graph2":"Phase I","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Capital Health, Canada | Dalhousie University | Universit\u00e9 de Montr\u00e9al","highestDevelopmentStatusID":"6","companyTruncated":"Nova Scotia Health Authority \/ Capital Health, Canada | Dalhousie University | Universit\u00e9 de Montr\u00e9al"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SCB-219M","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SCB-219M","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"NNC 0172-0000-2021","moa":"Tissue factor pathway inhibitor","graph1":"Hematology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BMS986141","moa":"TLR8 receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Pulmotect","sponsor":"National Heart, Lung, and Blood Institute | Cancer Prevention Research Institute of Texas","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"PUL-042","moa":"Toll-like-9 receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Pulmotect","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Pulmotect \/ National Heart, Lung, and Blood Institute | Cancer Prevention Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"Pulmotect \/ National Heart, Lung, and Blood Institute | Cancer Prevention Research Institute of Texas"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"ACE-536","moa":"Transforming growth factor beta","graph1":"Hematology","graph2":"Phase I","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Axis Clinicals Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Hematology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"AG-519","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agios Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Agios Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Xi'niao Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic anti-CD19","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Xi'niao Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Xi'niao Biotech"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ANX1502","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Velico Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Spray-Dried Plasma","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Velico Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Velico Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Velico Medical \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BAY3018250","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BAY3018250","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"CK0801","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellenkos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos \/ Undisclosed"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CS1-Sodium Valproate","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereno Scientific \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cereno Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CSJ137","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"DDO-3055","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Diakron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"DPOC-4088","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Diakron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Diakron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Diakron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Diakron Pharmaceuticals","sponsor":"University Ghent | Kinesis Pharma B.V.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"DPOC-4088","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Diakron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Diakron Pharmaceuticals \/ University Ghent | Kinesis Pharma B.V.","highestDevelopmentStatusID":"6","companyTruncated":"Diakron Pharmaceuticals \/ University Ghent | Kinesis Pharma B.V."},{"orgOrder":0,"company":"Chengdu Suncadia Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS-5965","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Chengdu Suncadia Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chengdu Suncadia Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Suncadia Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Changzhou No.2 People's Hospital","sponsor":"Rui Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KN5501","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Changzhou No.2 People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Changzhou No.2 People's Hospital \/ Rui Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Changzhou No.2 People's Hospital \/ Rui Therapeutics"},{"orgOrder":0,"company":"Immune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KQ-2003","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Immune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"NNC172-2021","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"NNC172-2021","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Chia-tai Tianqing Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NTQ5082","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Nanjing Chia-tai Tianqing Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nanjing Chia-tai Tianqing Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanjing Chia-tai Tianqing Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Chia-tai Tianqing Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NTQ5082","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Nanjing Chia-tai Tianqing Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nanjing Chia-tai Tianqing Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanjing Chia-tai Tianqing Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ONO-7746","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Orsenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ORH-2014","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Orsenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orsenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orsenix \/ Undisclosed"},{"orgOrder":0,"company":"Entegrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Plasma","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Entegrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entegrion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Entegrion \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Peg-Bio Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PN20","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Chongqing Peg-Bio Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Peg-Bio Biopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chongqing Peg-Bio Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Peg-Bio Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PN20","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Chongqing Peg-Bio Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chongqing Peg-Bio Biopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chongqing Peg-Bio Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"POZEN","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"PN400","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ POZEN","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ POZEN"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Bioheng Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RD13-02","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Bioheng Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Bioheng Biotech"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"LFB Group","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human Antithrombin","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mayo Clinic \/ LFB Group","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ LFB Group"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human TNF Receptor II-Fc-TPO Fusion Protein","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Orca Bio","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Regulatory T Cell","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Orca Bio","highestDevelopmentStatusID":"6","companyTruncated":"Stanford University \/ Orca Bio"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RLYB116","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"SHR2285","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SHR2285","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SHR2285","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Velico Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Spray-Dried Plasma","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Velico Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Velico Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Velico Medical \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"BioTrack Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ BioTrack Capital","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ BioTrack Capital"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SYHA136","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"V0355","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"China Immunotech","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"YTS109","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ China Immunotech","highestDevelopmentStatusID":"6","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ China Immunotech"},{"orgOrder":0,"company":"China Immunotech","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"YTS109","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"China Immunotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China Immunotech \/ Institute of Hematology & Blood Diseases Hospital, China","highestDevelopmentStatusID":"6","companyTruncated":"China Immunotech \/ Institute of Hematology & Blood Diseases Hospital, China"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Warfarin Sodium","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Hematology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Johnson & Johnson"},{"orgOrder":0,"company":"Suzhou Junjing BioSciences Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"WJ01024","moa":"XPO1","graph1":"Hematology","graph2":"Phase I","graph3":"Suzhou Junjing BioSciences Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Junjing BioSciences Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Suzhou Junjing BioSciences Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Queen's University","sponsor":"Unity Health Toronto | The Ottawa Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Queen's University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queen's University \/ Unity Health Toronto | The Ottawa Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Queen's University \/ Unity Health Toronto | The Ottawa Hospital"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Cadrenal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Frunexian","moa":"F11a","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Cadrenal Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ Cadrenal Therapeutics"},{"orgOrder":0,"company":"VarmX","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2025","type":"Collaboration","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase I","graph3":"VarmX","amount2":2.2200000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":2.2200000000000002,"dosageForm":"Infusion","sponsorNew":"VarmX \/ CSL","highestDevelopmentStatusID":"6","companyTruncated":"VarmX \/ CSL"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Cincinnati Children\u2019s Hospital Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Hematology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Drug Farm \/ Cincinnati Children\u2019s Hospital Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Cincinnati Children\u2019s Hospital Medical Center"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Lachelle D. Weeks, MD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Hematology","graph2":"Phase I","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astex Pharmaceuticals \/ Lachelle D. Weeks, MD, PhD","highestDevelopmentStatusID":"6","companyTruncated":"Astex Pharmaceuticals \/ Lachelle D. Weeks, MD, PhD"},{"orgOrder":0,"company":"Grifols International","sponsor":"Jonathan Stine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Antithrombin III","moa":"Serine protease","graph1":"Hematology","graph2":"Phase I","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Jonathan Stine","highestDevelopmentStatusID":"6","companyTruncated":"Grifols International \/ Jonathan Stine"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Anjali Sharathkumar","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Anjali Sharathkumar","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Anjali Sharathkumar"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Jennifer Woyach","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Hematology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Jennifer Woyach","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Jennifer Woyach"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
